Grace Makari-Judson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Grace Makari-Judson has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Bradley A. Arrick
Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
26 shared publications - Eugene Demidenko
Dartmouth College
26 shared publications - Fred Kolling
Dartmouth College
26 shared publications - Gary N. Schwartz
Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
26 shared publications - Jonathan D. Marotti
Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
26 shared publications - Karthik V. Giridhar
Department of Oncology, Mayo Clinic, Rochester, Minnesota
26 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer
Supplementary Fig. 1 CONSORT flow diagram of study patients. Among the 23 patients consented for study participation, 19 were considered evaluable.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer
Supplementary Fig. 1 CONSORT flow diagram of study patients. Among the 23 patients consented for study participation, 19 were considered evaluable.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Fig. 1 CONSORT flow diagram of study patients. Among the 23 patients consented for study participation, 19 were considered evaluable.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Fig. 1 CONSORT flow diagram of study patients. Among the 23 patients consented for study participation, 19 were considered evaluable.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Fig. 1 CONSORT flow diagram of study patients. Among the 23 patients consented for study participation, 19 were considered evaluable.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Fig. 1 CONSORT flow diagram of study patients. Among the 23 patients consented for study participation, 19 were considered evaluable.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Supplementary Tables 1-8 from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Purpose: Strategies to implement estrogen therapy for advanced estrogen receptor (ER)-positive breast cancer are under-developed. Preclinical data suggest that cycling treatment with 17b-estradiol followed by estrogen deprivation can control tumor growth long-term. Experimental Design: Post-menopausal women with advanced ER+/HER2- breast cancer with recurrence or progression on ≥1 anti-estrogen- or aromatase inhibitor (AI)-based therapy were eligible. Patients received 17b-estradiol (2 mg orally TID) for 8 weeks followed by AI (physician’s choice) for 16 weeks, alternating treatments on an 8-week/16-week schedule until disease progression. Patients then optionally received continuous single-agent treatment until a second instance of disease progression. Endpoints included 24-week clinical benefit and objective response per RECIST, and tumor genetic alterations. Results: Of 19 evaluable patients, clinical benefit rate was 42.1% (95% CI: 23.1-63.9%) and objective response rate was 15.8% (95% CI: 5.7-37.9%). One subject experienced a grade 3 adverse event related to 17b-estradiol. Among patients who received continuous single-agent treatment until a second instance of disease progression, clinical benefit was observed in 5/12 (41.7%) cases. Tumor ER (ESR1) mutations were found by whole-exome profiling in 4/7 (57.1%) vs. 2/9 (22.2%) patients who did vs. did not experience clinical benefit from alternating 17b-estradiol/AI therapy. The only two patients to experience objective responses to initial 17b-estradiol had tumor ESR1 mutations. Conclusions: Alternating 17b-estradiol/aromatase inhibitor therapy may be a promising treatment for endocrine-refractory ER+ breast cancer, including following progression on CDK4/6 inhibitors or everolimus. Further study is warranted to determine whether the anti-tumor activity of 17b-estradiol differs according to ESR1 mutation status.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer
Purpose: Strategies to implement estrogen therapy for advanced estrogen receptor (ER)-positive breast cancer are under-developed. Preclinical data suggest that cycling treatment with 17b-estradiol followed by estrogen deprivation can control tumor growth long-term. Experimental Design: Post-menopausal women with advanced ER+/HER2- breast cancer with recurrence or progression on ≥1 anti-estrogen- or aromatase inhibitor (AI)-based therapy were eligible. Patients received 17b-estradiol (2 mg orally TID) for 8 weeks followed by AI (physician’s choice) for 16 weeks, alternating treatments on an 8-week/16-week schedule until disease progression. Patients then optionally received continuous single-agent treatment until a second instance of disease progression. Endpoints included 24-week clinical benefit and objective response per RECIST, and tumor genetic alterations. Results: Of 19 evaluable patients, clinical benefit rate was 42.1% (95% CI: 23.1-63.9%) and objective response rate was 15.8% (95% CI: 5.7-37.9%). One subject experienced a grade 3 adverse event related to 17b-estradiol. Among patients who received continuous single-agent treatment until a second instance of disease progression, clinical benefit was observed in 5/12 (41.7%) cases. Tumor ER (ESR1) mutations were found by whole-exome profiling in 4/7 (57.1%) vs. 2/9 (22.2%) patients who did vs. did not experience clinical benefit from alternating 17b-estradiol/AI therapy. The only two patients to experience objective responses to initial 17b-estradiol had tumor ESR1 mutations. Conclusions: Alternating 17b-estradiol/aromatase inhibitor therapy may be a promising treatment for endocrine-refractory ER+ breast cancer, including following progression on CDK4/6 inhibitors or everolimus. Further study is warranted to determine whether the anti-tumor activity of 17b-estradiol differs according to ESR1 mutation status.